Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 24, 2020 (7 years ago)

Daptomycin

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack Of Processing Controls

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Daptomycin, 500MG in 0.9% NACL 100ML Injectable Redline Specialty Pharmacy, 2415 Osborne Drive E, #100 Hastings, NE 68901

Drug: Daptomycin

Recalling firm
Redline Pharmacy Solutions
Origin
NE, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1008-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Daptomycin recalls

See all
Class II · Moderate risk

Daptomycin

CGMP Deviations

Ongoing cGMP deviation Baxter Healthcare Corporation NDC 0338-0718-12 D-0821-2026
Class II · Moderate risk

Daptomycin

CGMP Deviations

Ongoing cGMP deviation Baxter Healthcare Corporation NDC 0338-0714-24 D-0807-2026

Other recalls by Redline Pharmacy Solutions

All 2020 recalls
Class II · Moderate risk

Morphine Sulfate

Lack Of Processing Controls

Terminated cGMP deviation Redline Pharmacy Solutions D-1011-2020
Class II · Moderate risk

Morphine Sulfate

Lack Of Processing Controls

Terminated cGMP deviation Redline Pharmacy Solutions D-1007-2020